Lansing, MI – According to filings with the U.S. Securities and Exchange Commission, NIOWAVE is raising $2,000,250.00 in new funding. Sources indicate as part of senior management Director, Roger Calantone played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About NIOWAVE
Niowave is a domestic supplier of medical and industrial radioisotopes from uranium fission and stable targets. Isotope inventories available for purchase include alpha, beta, and gamma sources. The system uses a superconducting linac instead of a nuclear reactor which is simpler to operate and less costly to license. It also eliminates the need for a nuclear reactor and weapons grade uranium (HEU). The small batch radiochemistry operations can be automated, and do not require licensing as a nuclear reprocessing facility.

To learn more about NIOWAVE, visit http://www.niowaveinc.com/

Contact:
Roger Calantone, Director
517-999-3475

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved